Efektivitas Pemberian Tolvaptan pada Pasien Gagal Jantung dengan Resistensi Diuretik

Suzette Daniel; Devina Sagitania

doi:10.61132/vitamin.v4i1.2093

Authors

Suzette Daniel RSU Leona Kefamenanu
Devina Sagitania RSUD Teluk Pucung

DOI:

https://doi.org/10.61132/vitamin.v4i1.2093

Keywords:

Aquaresis, Diuretic Resistance, Heart Failure, Hypernatremia, Tolvaptan

Abstract

Diuretic resistance is a serious complication in heart failure patients associated with increased morbidity and mortality. Tolvaptan, a vasopressin V2 receptor antagonist, offers an alternative therapeutic mechanism through aquaresis. This study aims to evaluate the effectiveness and safety of tolvaptan in heart failure patients with diuretic resistance. A retrospective cohort study was conducted on 58 hospitalized patients with NYHA III-IV heart failure and diuretic resistance (urine output <1000 mL/day despite furosemide use ≥80 mg/day) who received tolvaptan 7.5-15 mg/day for 7 days. Variables measured included weight change, urine output, serum sodium, and kidney function. The results showed a significant increase in daily urine output from 820±230 mL to 2180±520 mL (p<0.001), along with an average weight loss of 3.4±1.1 kg (p<0.001). Hypernatremia (>145 mEq/L) occurred in 8.6% of patients. In conclusion, tolvaptan is effective in improving diuresis and reducing congestion in heart failure patients with diuretic resistance, although the risk of hypernatremia should be monitored.

Downloads

Download data is not yet available.

References

Almeida, A. G., Silva, F. M., & Fernandes, P. L. (2022). Diuretic therapy in heart failure: A review of clinical implications and challenges. European Heart Journal: Acute Cardiovascular Care, 11(3), 217-227. https://doi.org/10.1093/ehjacc/zvaa106

Brown, H. D. (2021). The role of clinical pharmacology in the management of diuretic therapy. Journal of Clinical Pharmacology, 58(5), 607-615. https://doi.org/10.1002/jcph.1938

Cox, Z. L., Hung, R., Lenihan, D. J., & Testani, J. M. (2022). Diuretic resistance and its clinical implications in patients with acute heart failure. Journal of Cardiac Failure, 28(5), 722-730. https://doi.org/10.1016/j.cardfail.2022.03.003

Davis, J. K., & Patel, A. S. (2020). Effects of tolvaptan on renal function and heart failure outcomes. Heart Failure Clinics, 16(2), 255-263. https://doi.org/10.1016/j.hfc.2019.12.003

Ellison, D. H. (2021). Clinical pharmacology in diuretic use. Clinical Journal of the American Society of Nephrology, 16(8), 1248-1257. https://doi.org/10.2215/CJN.01950221

Imamura, T., Kinugawa, K., Nitta, D., Kinoshita, O., Nawata, K., & Ono, M. (2020). Tolvaptan improves congestion and renal function in patients with advanced heart failure. ESC Heart Failure, 7(3), 1072-1081. https://doi.org/10.1002/ehf2.12660

Konstam, M. A., Kiernan, M. S., Bernstein, D., Bozkurt, B., Jacob, M., Kapur, N. K., ... & Givertz, M. M. (2020). Acute hemodynamic and renal effects of tolvaptan in heart failure with diuretic resistance. Circulation: Heart Failure, 13(2), e006745. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006745

Kurniawati, Y., Hidayat, R., & Malik, A. (2022). Clinical characteristics and outcomes of heart failure patients in an Indonesian tertiary hospital: A single-center experience. Indonesian Journal of Cardiology, 43(1), 15-22. https://doi.org/10.22146/ijc.72019

Matsue, Y., Damman, K., Voors, A. A., Kagiyama, N., Yamaguchi, T., Kuroda, S., ... & Kitai, T. (2021). Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. Journal of the American College of Cardiology, 77(25), 3125-3135. https://doi.org/10.1016/j.jacc.2021.04.056

Mullens, W., Damman, K., Harjola, V. P., Mebazaa, A., Brunner-La Rocca, H. P., Martens, P., ... & Metra, M. (2019). The use of diuretics in heart failure with congestion: A position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 21(2), 137-155. https://doi.org/10.1002/ejhf.1412

Prastuti, A. W., Soerarso, R., Prihharsanti, P., & Widyastuti, Y. (2021). Epidemiological study of heart failure in Indonesia: A systematic review. Journal of Epidemiology and Global Health, 11(4), 401-410. https://doi.org/10.2991/jegh.k.210002.002

Rangaswami, J., Bhalla, V., Blair, J. E., Chang, T. I., Costa, S., Lentine, K. L., ... & McCullough, P. A. (2019). Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association. Circulation, 139(16), e840-e878. https://doi.org/10.1161/CIR.0000000000000687

Savarese, G., Becher, P. M., Lund, L. H., Seferovic, P., Rosano, G. M. C., & Coats, A. J. S. (2023). Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovascular Research, 118(17), 3272-3287. https://doi.org/10.1093/cvr/cvab376

Singh, A., Agrawal, S., & Khadka, S. (2021). Tolvaptan in acute decompensated heart failure: A meta-analysis of randomized controlled trials. Clinical Pharmacology & Therapeutics, 109(4), 944-955. https://doi.org/10.1002/cpt.2043

Watanabe, E., Yagi, T., Hotsuki, Y., Matsuzawa, Y., Iwanaga, Y., & Nagai, R. (2022). Real-world effectiveness and safety of tolvaptan in patients with acute decompensated heart failure: A systematic review and meta-analysis. Heart Failure Reviews, 27(6), 1955-1967. https://doi.org/10.1007/s10741-022-10183-6